Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Pediatr Allergy Immunol ; 32(3): 479-488, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33207014

RESUMO

BACKGROUND: Vitamin D supplementations for asthma control had shown inconsistent results. We aimed to study efficacy and safety of vitamin D supplementation in asthmatic children who were vitamin D deficient. METHODS: This double-blind, randomized controlled trial enrolled asthmatic children of 4-12 years of age who had 25-hydroxyvitamin D [25(OH)D] levels <20 ng/mL. The participants were randomized to receive either vitamin D orally 1000 IU/d for 9 months or similar-looking placebo. The primary outcomes were the proportion of children having the Childhood Asthma Control Test (CACT) score of ≥20 at the end of the treatment and adverse effects. RESULTS: The trial included 250 children (125 in each group) with a mean age of 8.1 ± 2.3 years and 180 boys. The baseline parameters were similar between the groups, including CACT score (21.7 ± 4.2 vs 21.9 ± 3.6, vitamin D vs placebo). At the end of the study, the proportion of asthmatic children who had CACT score ≥ 20 was similar between vitamin D and placebo group (93.6% vs 92.0%, P = .625). The number of exacerbations of asthma and side effect profile was also identical between the groups. 25(OH)D levels increased significantly in the vitamin D group (18.06 ± 7.11 vs 12.03 ± 5.98 ng/mL, P < .001). The results did not change when we did subgroup analysis for children with baseline CACT score < 20 and 25(OH)D levels at the end of the study ≥20 ng/mL. CONCLUSION: Vitamin D supplementation in asthmatic children with vitamin D deficiency did not improve control of asthma.


Assuntos
Asma , Deficiência de Vitamina D , Asma/tratamento farmacológico , Criança , Colecalciferol , Suplementos Nutricionais , Método Duplo-Cego , Humanos , Recém-Nascido , Masculino , Vitamina D , Deficiência de Vitamina D/complicações , Deficiência de Vitamina D/tratamento farmacológico
2.
Drug Dev Res ; 79(4): 173-183, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29989222

RESUMO

S009-0629 [methyl-8-(methylthio)-2-phenyl-6-p-tolyl-4,5-dihydro-2H-benzo[e]indazole-9-carboxylate] is a novel antidiabetic agent with PTP1B inhibitory activity. In this study, we have investigated the in vitro metabolic stability, plasma protein binding, blood partitioning, and oral pharmacokinetic study of S009-0629 in rats. The plasma protein binding, blood partitioning, and metabolic stability were determined by HPLC method. The oral pharmacokinetic study was analyzed by liquid chromatography coupled mass spectrometry (LC-MS/MS) method. The plasma protein binding of S009-0629 using modified charcoal adsorption method at 5 and 10 µg/mL was 80.58 ± 1.04% and 81.95 ± 1.15%, respectively. The KRBC/PL of S009-0629 was independent of concentration and time. The in-vitro half-life of S009-0629 at 5 and 10 µM using rat liver microsomes was determined as 273 ± 24.46 and 281.67 ± 26.53 min, respectively. After oral administration, S009-0629 exhibited Cmax 55.51 ± 1.18 ng/mL was observed at 18 hr (tmax ). S009-0629 was found to have the large apparent volume of distribution (1,894.93 ± 363.67 L/kg). Oral in-vivo t1/2 of S009-0629 was found to be 41.23 ± 5.96 hr. A rapid and highly sensitive LC-MS/MS method was validated for S009-0629 in rat plasma. S009-0629 has high plasma protein binding and low hepatic extraction. S009-0629 has no affinity with human P-gp and BCRP in ATPase assay. After oral dosing, S009-0629 has slow absorption and elimination in rats.


Assuntos
Proteínas Sanguíneas/metabolismo , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/farmacocinética , Indazóis/farmacocinética , Microssomos Hepáticos/metabolismo , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP/metabolismo , Administração Oral , Animais , Disponibilidade Biológica , Humanos , Hipoglicemiantes/sangue , Hipoglicemiantes/metabolismo , Indazóis/administração & dosagem , Indazóis/sangue , Masculino , Proteínas de Neoplasias/metabolismo , Ligação Proteica , Ratos
3.
Medchemcomm ; 8(2): 329-337, 2017 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-30108748

RESUMO

Based on high throughput screening of our chemical library, we identified two 4,5-dihydro-2H-benzo[e]indazole derivatives (5d and 5g), which displayed a significant effect on glucose uptake in L6 skeletal muscle cells. Based on these lead molecules, a series of benzo[e]indazole derivatives were prepared. Among all the synthesized dihydro-2H-benzo[e]indazoles, 8-(methylthio)-2-phenyl-6-p-tolyl-4,5-dihydro-2H-benzo[e]indazole-9-carboxylate (5e) showed significant glucose uptake stimulation in L6 skeletal muscle cells, even better than lead compounds. Additionally, 5e decreased glucagon-induced glucose release in HepG2 hepatoma cells. The 2H-benzo[e]indazole 5e exerted an antihyperglycemic effect in normal, sucrose challenged streptozotocin-induced diabetic rats and type 2 diabetic db/db mice. Treatment with 5e at a dose of 30 mg kg-1 in db/db mice caused a significant decrease in triglyceride and total cholesterol levels and increased the HDL-C level in a significant manner. The mechanistic studies revealed that the 2H-benzo[e]indazole 5e significantly stimulated insulin-induced signaling at the level of IRS-1, Akt and GSK-3ß in L6 skeletal muscle cells, possibly by inhibiting protein tyrosine phosphatase-1B. This new 2H-benzo[e]indazole derivative has potential for the treatment of diabetes with improved lipid profile.

4.
PLoS One ; 10(12): e0144541, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26657206

RESUMO

We evaluated the bone regeneration and healing effect of Medicarpin (med) in cortical bone defect model that heals by intramembranous ossification. For the study, female Sprague-Dawley rats were ovariectomized and rendered osteopenic. A drill hole injury was generated in mid femoral bones of all the animals. Med treatment was commenced the day after and continued for 15 days. PTH was taken as a reference standard. Fifteen days post-treatment, animals were sacrificed. Bones were collected for histomorphometry studies at the injury site by micro-computed tomography (µCT) and confocal microscopy. RNA and protein was harvested from newly generated bone. For immunohistochemistry, 5µm sections of decalcified femur bone adjoining the drill hole site were cut. By µCT analysis and calcein labeling of newly generated bone it was found that med promotes bone healing and new bone formation at the injury site and was comparable to PTH in many aspects. Med treatment led to increase in the Runx-2 and osteocalcin signals indicating expansion of osteoprogenitors at the injury site as evaluated by qPCR and immunohistochemical localization. It was observed that med promoted bone regeneration by activating canonical Wnt and notch signaling pathway. This was evident by increased transcript and protein levels of Wnt and notch signaling components in the defect region. Finally, we confirmed that med treatment leads to elevated bone healing in pre-osteoblasts by co localization of beta catenin with osteoblast marker alkaline phosphatase. In conclusion, med treatment promotes new bone regeneration and healing at the injury site by activating Wnt/canonical and notch signaling pathways. This study also forms a strong case for evaluation of med in delayed union and non-union fracture cases.


Assuntos
Osso e Ossos/patologia , Pterocarpanos/farmacologia , Receptores Notch/metabolismo , Via de Sinalização Wnt/efeitos dos fármacos , Cicatrização/efeitos dos fármacos , Animais , Biomarcadores/metabolismo , Densidade Óssea/efeitos dos fármacos , Doenças Ósseas Metabólicas/tratamento farmacológico , Doenças Ósseas Metabólicas/fisiopatologia , Regeneração Óssea/efeitos dos fármacos , Regeneração Óssea/genética , Osso e Ossos/efeitos dos fármacos , Osso e Ossos/fisiopatologia , Diferenciação Celular/efeitos dos fármacos , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Ovariectomia , Ratos Sprague-Dawley , Coloração e Rotulagem , Células-Tronco/citologia , Células-Tronco/efeitos dos fármacos , Células-Tronco/metabolismo
5.
Planta Med ; 74(10): 1308-15, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18553273

RESUMO

The quality control of medicinal herbs post harvesting or after collection becomes very critical because of susceptibility to fungal invasion during storage depending on the temperature and humidity of the storage area. The information on moisture equilibrium is important on the process and storage of foods which can be extended to medicinal herbs. In the present study, the growth of Aspergillus flavus was observed on selected ten medicinal herbs with water activity aw above 0.81 when stored at 25 +/- 2 degrees C, 30 +/- 2 degrees C and 40 +/- 2 degrees C except for Picrorhiza kurrooa and Alpinia galanga which were found to have anti-fungal properties. Aspergillus flavus did not grow in any samples of medicinal herbs with water activity aw below 0.81 at temperatures of 25 +/- 2 degrees C, 30 +/- 2 degrees C and 40 +/- 2 degrees C. Also Aspergillus flavus did not grow in any samples of medicinal herbs with water activity aw above 0.81 when stored below 10 +/- 2 degrees C. Therefore it can be concluded that the contamination of medicinal herbs with aflatoxins can be minimized by controlling water activity and storage temperature. Sorption isotherms (desorption) can be interpreted to determine the optimum drying which can lower the water activity to the level required for preventing growth of Aspergillus flavus and also for ensuring quality of medicinal herbs which may get destroyed upon over drying. Furthermore, it also saves incremental cost in prolonged drying over the optimum drying.


Assuntos
Aspergillus flavus/crescimento & desenvolvimento , Plantas Medicinais/microbiologia , Temperatura , Água/análise , Dessecação , Plantas Medicinais/química , Controle de Qualidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA